Modular Bioscience, an innovative biotechnology company headquartered in Silicon Valley, USA, today announced that it has signed a final agreement with the University of Illinois at Urbana-Champaign to acquire the school's artificial restriction enzymes (AREs). Exclusive global patent license for the platform. This technology platform was developed by Professor Zhao Huimin and his team at the University of Illinois at Urbana-Champaign, and can be used for basic biology and applied biology research, as well as medical research and diagnosis. Modular Bioscience's initial focus will be on synthetic biology, diagnostics of genetic diseases, liquid biopsies, and detection of infectious diseases including COVID-19. "Because of ARE's unprecedented simplicity, programmability, and ease of use, ARE will become a powerful and indispensable tool in basic biological research and biotechnology applications of all nucleases," Dr. Zhao predicted. It should be as significant to molecular biology as CRISPR technology is to cell biology." Dr. Zhang Zhaohui, President and CEO of Modular Bioscience, said: "We are excited to apply this world's only technology platform to scientific research and infectious diseases. To develop new products and technologies in various fields such as detection, we believe that this unique platform can reduce the cost and time of the above various applications by at least ten times. In addition, we are also happy to license this new technology to other collaborators to benefit mankind. "We are collaborating with Modular Bioscience to advance this promising technology platform that has the potential to create powerful new tools for molecular biology research," added Mariana Lencina, MS , Technology Manager in the Office of Technology Management at the University of Illinois at Urbana -Champaign. .”